Shanghai Henlius (复宏汉霖) IPO: Not an Impressive Biosimilar Portfolio
Shanghai Henlius, a subsidiary of Fosun Pharma, is seeking to list in Hong Kong. In this insight, we will discuss the following topics: The...
1.1k Views
CStone Pharma IPO Preview: Mixed Prospects of Late-Stage Clinical Drug Candidates
CStone Pharma (CSTONE HK) is a biopharmaceutical company which is developing a pipeline of 14 drug candidates of which 9 are in clinical...
669 Views
Last Week in GER IPO Research: Leong Hup, China Tobacco, Futu and Weimob
We slide into 2019 with GER's recap of our latest IPO research. This week, we talk chicken as Arun initiates on the IPO Malaysian poultry producer...
630 Views
Last Week’s GER IPO Research: Tencent Music, IPO Trading Strategy Deep Dive, WuXi, Junshi & Xinyi
Another busy week for IPO research from the GER team. This week, we recap the Tencent Music Entertainment (TME US) IPO which we noted is more...
439 Views
Junshi Bioscience (君实医药) IPO: Rich Valuation, but Catalyst Ahead
Shanghai Junshi Biosciences, a China-based biotechnology company listed on the NEEQ market (ticker 833330.NEEQ) with a market capitalization of USD...
829 Views